<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914520</url>
  </required_header>
  <id_info>
    <org_study_id>VN0200-A-J101</org_study_id>
    <secondary_id>jRCT2031210069</secondary_id>
    <nct_id>NCT04914520</nct_id>
  </id_info>
  <brief_title>Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of VN-0200 After Intramuscular Injections in Japanese Healthy Adults and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, and immunogenicity of VN-0200 after&#xD;
      intramuscular injections in Japanese healthy adults and elderly subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Treatment-emergent Adverse Events</measure>
    <time_frame>From first administration through 28 days post second administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Local and Systemic Adverse Events</measure>
    <time_frame>From first administration up to 14 days after second administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events</measure>
    <time_frame>From date of informed consent up to approximately 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Anti-RSV Specific Neutralizing Activity</measure>
    <time_frame>Day 29 and Day 57 post-dose and at the time of discontinuation (whichever occurs first), up to approximately 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Anti-VAGA-9001a IgG</measure>
    <time_frame>Day 1 (pre-dose), Day 29 and Day 57 post-dose, and at the time of discontinuation (whichever occurs first), up to approximately 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Anti-RSV IgG</measure>
    <time_frame>Day 1 (pre-dose), Day 29 and Day 57 post-dose, and at the time of discontinuation (whichever occurs first), up to approximately 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of IFN-γ spot-forming cells in PBMC Detected by ELISPOT</measure>
    <time_frame>Day 1 (pre-dose), Day 29 and Day 57 post-dose, and at the time of discontinuation (whichever occurs first), up to approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Step 1: VN-0200 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 1: VN-0200 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 1: VN-0200 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy adults and elderly subjects will be randomized to receive intramuscular injection of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2: VN-0200 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2: VN-0200 dose medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2: VN-0200 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy adults and elderly subjects will be randomized to receive intramuscular injection of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VN-0200</intervention_name>
    <description>VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total</description>
    <arm_group_label>Step 1: VN-0200 high dose</arm_group_label>
    <arm_group_label>Step 1: VN-0200 low dose</arm_group_label>
    <arm_group_label>Step 1: VN-0200 medium dose</arm_group_label>
    <arm_group_label>Step 2: VN-0200 dose medium dose</arm_group_label>
    <arm_group_label>Step 2: VN-0200 high dose</arm_group_label>
    <arm_group_label>Step 2: VN-0200 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total</description>
    <arm_group_label>Step 1: Placebo</arm_group_label>
    <arm_group_label>Step 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese&#xD;
&#xD;
          -  Healthy adults aged ≥20 and ≤50 years (Step 1) or healthy elderly aged ≥65 and ≤80&#xD;
             years (at the time of informed consent)&#xD;
&#xD;
          -  Body mass index (BMI) is ≥18.0 and &lt;30.0 kg/m^2 (at screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with a history of anaphylaxis or severe allergies due to food, medicine,&#xD;
             insect bites, cosmetics, or vaccination&#xD;
&#xD;
          -  Having alcohol or drug dependence, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Corporation Association Shinanokai Shinanozaka Clinic</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus Infections</keyword>
  <keyword>VN0200</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

